Gaspard GJ, MacLean J, Rioux D, Pasumarthi KB. A novel ␤-adrenergic response element regulates both basal and agonistinduced expression of cyclin-dependent kinase 1 gene in cardiac fibroblasts. Am J Physiol Cell Physiol 306: C540 -C550, 2014. First published January 29, 2014; doi:10.1152/ajpcell.00206.2013.-Cardiac fibrosis, a known risk factor for heart disease, is typically caused by uncontrolled proliferation of fibroblasts and excessive deposition of extracellular matrix proteins in the myocardium. Cyclin-dependent kinase 1 (CDK1) is involved in the control of G 2/M transit phase of the cell cycle. Here, we showed that isoproterenol (ISO)-induced cardiac fibrosis is associated with increased levels of CDK1 exclusively in fibroblasts in the adult mouse heart. Treatment of primary embryonic ventricular cell cultures with ISO (a nonselective ␤-adrenergic receptor agonist) increased CDK1 protein expression in fibroblasts and promoted their cell cycle activity. Quantitative PCR analysis confirmed that ISO increases CDK1 transcription in a transient manner. Further, the ISO-responsive element was mapped to the proximal Ϫ100-bp sequence of the CDK1 promoter region using various 5=-flanking sequence deletion constructs. Sequence analysis of the Ϫ100-bp CDK1 minimal promoter region revealed two putative nuclear factor-Y (NF-Y) binding elements. Overexpression of the NF-YA subunit in primary ventricular cultures significantly increased the basal activation of the Ϫ100-bp CDK1 promoter construct but not the ISO-induced transcription of the minimal promoter construct. In contrast, dominant negative NF-YA expression decreased the basal activity of the minimal promoter construct and ISO treatment fully rescued the dominant negative effects. Furthermore, site-directed mutagenesis of the distal NF-Y binding site in the Ϫ100-bp CDK1 promoter region completely abolished both basal and ISO-induced promoter activation of the CDK1 gene. Collectively, our results raise an exciting possibility that targeting CDK1 or NF-Y in the diseased heart may inhibit fibrosis and subsequently confer cardioprotection.
CARDIOVASCULAR DISEASE REMAINS one of the leading causes of death globally. For the past few decades, the scientific community has studied various mechanisms responsible for heart disease with a focus on cardiomyocytes. Nevertheless, recent research on cardiac nonmyocytes has demonstrated the sentinel role of cardiac fibroblasts in cardiac development and remodeling in both health and disease states (3, 8, 21, 50, 55) . Uncontrolled proliferation of cardiac fibroblasts resulting in increased synthesis and deposition of the extracellular matrix is noted in heart disease arising from different etiologies (42) .
Heart failure, myocardial infarction, and chronic hypertrophy induced by pressure overload, myocardial ischemia, or sustained activation of sympathetic and renin-angiotensin-aldosterone systems are characterized by cardiomyocyte necrosis/ apoptosis and cell loss (41, 42, 53) . The dead myocytes are replaced with proliferating cardiac fibroblasts and newly synthesized collagen matrix. High circulating and tissue levels of the catecholamine norepinephrine were correlated with the incidence of left ventricular hypertrophy in both hypertensive and normotensive patients (23, 45, 46) . Chronic stimulation of myocardium by natural or synthetic catecholamines such as isoproterenol (ISO) in animal models is known to induce cardiac hypertrophy, fibroblast proliferation, and fibrosis (4, 17, 19, 38, 40, 54) .
Blockers of sympathetic nervous system and renin-angiotensin-aldosterone are known to modulate cardiac fibroblast function (42) . While there is growing body of knowledge on the subject of phenocoversion of fibroblasts to myofibroblasts (12, 49) , additional studies are required to characterize the mechanisms involved in the regulation of fibroblast proliferation during disease states. Identification of key cell cycle regulators in diseased hearts may serve as effective drug targets to control cardiac fibrosis (1, 34, 35) . A previous study showed that treatment with ISO induced expression of cell cycle proteins and subsequently acinar cell proliferation in rodent salivary glands (61) . Particularly, this study reported significant increases in protein levels of cyclin-dependent kinase 1 (CDK1) and the activity of the CDK1/cyclin B complex in salivary glands subjected to ISO treatment compared with the controls. CDK1 interacts with cyclin B1 and regulates the transition between the G 2 and M phases of the cell cycle. The expression of CDK1 is downregulated in the adult heart, and the status of CDK1 expression after catecholamine stimulation has not been explored.
The objectives of this study were to determine the effects of ISO on CDK1 levels in the mouse heart and to identify the mechanisms involved in the ISO-induced effects on CDK1 levels. Cardiac hypertrophy and fibrosis were induced in mice by chronic ISO administration. We found that ISO induced CDK1 expression in noncardiomyocytes in the adult mouse heart. Treatment with ISO activated noncardiomyocyte proliferation in primary embryonic ventricular myocardial cell cultures. Analysis of the CDK1 promoter constructs revealed that transcriptional activation by ISO occurs via a nuclear factor-Y (NF-Y) binding site. Dominant negative and site directed mutagenesis approaches further confirmed the involvement of NF-Y in both basal and ␤-adrenergic stimulation of CDK1 promoter activity.
MATERIALS AND METHODS
Experimental animals, induction of cardiac hypertrophy, and primary ventricular cell cultures. All animal procedures were performed according to the Canadian Council on Animal Care guidelines and were approved by the Dalhousie University Committee on Laboratory Animal Care. Adult male CD1 mice (11-13 wk old) received either ISO (20 g/g body wt/day) or saline via mini-osmotic pumps (model 2001; Alzet, Palo Alto, CA; ϳ200-l fill volume/pump, flow rate of 1 l/h) for 7 days. Body weights of mice used in this study were recorded before and immediately after the implantation of mini osmotic pumps. Body weights were also recorded again 7 days after implantation of the pump before animals were euthanized.
Adult cardiac fibroblasts were prepared by the methods described earlier (24, 28) with minor modifications. In brief, ventricles were harvested from male CD1 mice (11-15 wk old), finely minced, and digested in 0.1% collagenase (wt/vol; Worthington Biochemical, Lakewood, NJ) at 37°C for 15 min. The cells that were dissociated from the first and second digestions were discarded. The cells that were dissociated from the third, fourth, and fifth digestions were pooled and plated in 10% FBS-DMEM. Media were changed after 1 h to eliminate unattached or weakly adherent cells such as cardiomyocytes and endothelial cells. Embryonic day 15.5 (E15.5) primary cultures composed of ventricular myocytes and fibroblasts were generated as described earlier (36, 52) . In brief, female CD1 mice were time-mated to obtain E15.5 embryos. The atria were removed from the embryonic hearts, the ventricles were digested with 0.1% collagenase, and the dispersed cells were cultured on fibronectin-coated 3-mm culture dishes (Corning, Corning, NY) overnight in 10% FBS-DMEM at a cell density of 1,000,000 million cells per dish.
Histology and immunofluorescence staining. Ten-micrometer cryosections were obtained from the adult hearts and processed for visualization of fibrosis by Picro Sirius Red (Direct Red 80 CI 35780; Sigma) and Fast Green (FCF CI 42053; Fisher) (PSFG) staining as described earlier (14, 15) . Cryosections or cultured cells were incubated with primary antibodies for CDK1 (sc-954; Santa Cruz Biotechnology, Santa Cruz, CA), sarcomeric myosin [MF-20; Developmental Studies Hybridoma Bank (DSHB), University of Iowa], von Willebrand factor (sc-14014), DDR2 (sc-8989), and ␣-smooth muscle actin (1E12-s; DSHB), followed by anti-rabbit and or anti-mouse secondary antibodies conjugated to Alexafluor 488 and 555 (Invitrogen) as described in our earlier publications (36, 52, 56) . The samples were examined using a Leica DM2500 epifluorescence microscope fitted with Leica DFC500 digital acquisition system. DNA constructs and transfections. Generation of the human CDK1 promoter constructs was previously reported (6) , and these constructs were received as generous gifts from Dr. Teresa Born (Amgen). In brief, the 6.2-kb 5=-flanking sequence or various deletions of the human CDK1 gene were cloned upstream of the luciferase reporter gene in the pGL2 basic vector. These constructs were designated as Ϫ6.2-kb, Ϫ1.8-kb, Ϫ1.1-kb, Ϫ700-bp, Ϫ245-bp, and Ϫ100-bp CDK1p-luc. Cloning of the mouse wild-type NF-YA and its dominant negative version (NF-YADN) in a poly II vector was previously described (47, 57) , and these constructs were received as generous gifts from Dr. Roberto Mantovani (University of Milan, Milan, Italy). The NF-YADN sequence has three point mutations in the DNA binding region of the NF-YA subunit (33) . The empty poly II plasmid was used as a vector control in our NF-YA subunit overexpression studies. The CDK1p-luc construct harboring mutations in the distal NF-Y binding site (Ϫ100-bp CDK1p-NF-Y MTB-luc) was generated by using the Quick change II site directed mutagenesis kit as directed by the manufacturer (Agilent Technologies). Briefly, 5 ng of Ϫ100-bp CDK1p-luc plasmid were PCR amplified in the presence of 125 ng of forward (NFmtS) and reverse (NFmtAS) primers (see Table 1 for primer sequence) both harboring the desired NF-Y binding site mutations (5=-ATTGG-3= to ACCGG). After amplification, the above mixture was digested with the restriction enzyme Dpn I (provided in the kit) to specifically degrade the wild-type Ϫ100-bp CDK1p-luc plasmid. Following the restriction digest, the mutated sequences were transformed in XL 1 blue competent cells to obtain the Ϫ100-bp CDK1p-NF-Y MTB-luc plasmid. The introduced point mutations were further confirmed by sequencing (DALGene Sequencing Facility, Dalhousie University).
Transient DNA transfections of CDK1p-luc, NF-YA, NF-YADN, and poly II constructs in cultured E15.5 cells were performed by Lipofectamine 2000 transfection reagent (Invitrogen) as directed by the manufacturer. For the luciferase reporter gene assay and quantitative (q)PCR analysis, cells were transfected with 4 and 0.4 g of the indicated CDK1p-luc and pRL-TK-renilla constructs, respectively. E15.5 cells that were used in reporter assays coupled with NF-Y subunit overexpression were transfected with 4 g of NF-YADN or polyII vector and 600 ng of NF-YA subunits, respectively, along with the cdk1p-luc and pRL-TK-renilla constructs as indicated above.
Drug treatments, tritiated thymidine autoradiography, and reporter gene assays. Adult cardiac fibroblast cultures were treated with 1 M ISO or 10 M norepinephrine (NE) for 48 h. Subsequently, these cultures were processed for immunofluorescence staining for CDK1 expression using methods described earlier (52) . ISO and NE were purchased from Sigma-Aldrich (Oakville, ON, Canada), and the drug stocks were prepared fresh for each experiment. Control cultures were treated with vehicle alone. The E15.5 ventricular cells were treated with 1 M ISO for 48 h and in some cases also pulsed with [ 3 H]thymidine after which they were processed for immunofluorescence staining and tritiated thymidine uptake assay, as described earlier (52, 56) . Cardiomyocyte and noncardiomyocyte DNA synthesis levels were measured by quantifying cells stained with MF20 (a cardiomyocyte marker) containing silver grains, vs. cells negative for MF20 staining but positive for silver grains. The estimates of cell cycle activity assessed by DNA synthesis were expressed as mean percent thymidine positive cells Ϯ SE. For transcriptional regulation studies, transfected E15.5 cells were treated with 1 M ISO in serum free DMEM for 24 h. Reporter gene assays were performed using a dual luciferase reporter assay kit (Promega, Madision, WI) according to the manufacturer's instructions. The luminescence from the renilla luciferase served as an internal control to correct for variations in transfection efficiency. The reporter experiments were repeated three times, and the promoter activity was expressed as mean luciferase relative light units (RLU) per renilla RLU per milligrams of protein (corrected RLUs) Ϯ SE.
RNA preparation and quantitative PCR. Total RNA was isolated from E15.5 cell cultures using Trizol reagent (Invitrogen), and cDNA was synthesized from total RNA using Superscript II reverse transcriptase (Invitrogen). For each new RNA sample, two controls were set up; a no-template control and a no-enzyme control, where sterile water replaced the omitted enzyme or RNA. The cDNA was amplified by qPCR using primers (Table 1 ) specific for CDK1 and RPB1 (RNA polymerase II largest subunit). The reaction mixture consisted of 2 l of cDNA product, 1 l of the forward and reverse primers (2.5 M), 10 l of 2ϫ Brilliant II SYBER Green Master Mix (Stratagene, La Jolla, CA), 0.5 l of 1:1000 Rox reference dye, and 5.5 l RNase/ DNase free dH 2O. qPCR conditions were set on the MX3000P thermocycler (Stratagene) as follows: 95°C for 10 min followed by 45 cycles each consisting of 95°C for 20 s, 60°C for 18 s, and 72°C for 30 s. Once the amplification cycles were completed, melting curves were generated by an additional cycle to verify the amplification of one gene per primer pair. Primers were designed to be exon spanning so as to eliminate genomic DNA amplification. Gene expression was normalized to a control reference gene (RPB1) using the ⌬⌬C T method.
Western blotting. Protein samples were harvested, run on polyacrylamide gels, and transferred to nitrocellulose membrane as described previously (14, 56) . The nitrocellulose blots were blocked for an hour by incubating in blocking buffer (5% milk, 3% BSA, and 0.1% Tween in PBS). The blots were then incubated in 1:400 dilutions of cdk1 (sc-954; Santa Cruz) and ␣-tubulin (sc-8035; Santa Cruz) and 1:200 dilutions of cdk1-tyr-PO 4 (sc-79789; Santa Cruz), NF-YA (sc-10779; Santa Cruz), and NF-YB (sc-13045; Santa Cruz) antibodies in blocking buffer for 1 h. After incubation, the blots were washed three times (5 min each wash) with wash buffer (0.1% Tween in PBS) and then were incubated with 1:1,000 dilutions of either anti-rabbit or anti-mouse antibodies conjugated to peroxidase in blocking buffer for another 45 min. The blots were washed three times in wash buffer, and ECL reagent (GE, Biosciences) was used to detect the peroxidase signals in the blot as directed by the manufacturer.
Statistical analysis. Data are presented as means Ϯ SE. Multiple group comparisons and between group comparisons were analyzed by ANOVA with Tukey's multiple comparisons test and Student's t-test, respectively. All of these analyses were performed using Graphpad Prism (Graphpad Software, San Diego, CA).
RESULTS

ISO treatment increases CDK1 expression preferentially in cardiac fibroblasts under both in vivo and in vitro conditions.
The goal of this study was to investigate the effect of chronic exposure to ISO on CDK1 levels in the mouse heart. To this end, adult mice were continuously infused with ISO or saline for 7 days and the onset of cardiac hypertrophy was confirmed by a significant increase in the heart weight to body weight ratios of ISO-treated mice compared with the control group (heart weight-to-body weight ratios: ISO: 5.5 Ϯ 0.1 mg/g vs. Fig. 1 . Continuous infusion of isoproterenol (ISO) for 7 days via miniosmotic pumps induces cardiac fibrosis and cyclin-dependent kinase 1 (CDK1) expression in noncardiomyocytes of the adult mouse heart. A and B: representative Picro Sirius red and Fast Green (PSFG)-stained heart section from saline-and ISO-treated mouse hearts. Note the absence of Sirius Red-stained fibrosis in the saline-treated heart (A) and the presence of interstitial fibrosis in the ISO-treated heart (B). C-G: representative heart sections from saline (C and D)-and ISO (E-G)-treated hearts were labeled with antibodies specific for CDK1 (red, C and E) and sarcomeric myosin MF20 (green, D and F). D and F: merged images of both CDK1 and MF20 stainings. G represents a higher magnification corresponding to the area labeled by an * in F. Note the absence of CDK1 staining in MF20-labeled myocytes. H: Western blot analysis of CDK1 protein levels in heart lysates from saline (lane 1)-or ISO (lane 2)-treated mice. CDK1 corresponds to the 34-kDa band labeled by an arrowhead. Bottom band is a nonspecific protein band reactive to the CDK1 antibody. Scale bar ϭ 100 m in A-F; n ϭ 3 independent experiments. saline: 4.3 Ϯ 0.04 mg/g; P Ͻ 0.05). Subsequently, cryosections generated from these hearts were stained with PSFG staining to identify fibrotic areas. PSFG staining revealed more extensive fibrosis in ISO-treated mice compared with saline-treated controls (Fig. 1, A and B) . Cryosections from the hearts of mice treated with or without ISO for 7 days were subjected to immunostaining analysis and labeled with antibodies specific for CDK1 and sarcomeric myosin to determine the cellular localization of induced CDK1 expression in the adult mouse heart. While CDK1 was undetectable in saline-treated hearts (Fig. 1, C and D) , ISO-induced CDK1 expression was found to be localized to the nonmyocyte compartment (Fig. 1, E-G) . Subsequently, Western blotting was performed on protein lysates obtained from adult mouse hearts. Control lysates from saline-treated adult hearts did not show detectable levels of CDK1 expression. Consistent with immunostaining results, ISO treatment induced CDK1 expression in the adult mouse heart (Fig. 1H) .
Subsequently, CDK1 expression in response to ISO treatment was examined in vitro using two primary culture models. In the first set of experiments, we cultured primary cardiac fibroblasts isolated from adult mouse ventricles. Immunostaining analysis revealed that nearly 100% of first passage cells stained positive for ␣-smooth muscle actin, an established marker for adult cardiac fibroblasts (44) (Fig. 2A) . These adult cardiac fibroblast cultures were also negative for sarcomeric myosin or endothelial cell markers (data not shown). Adult cardiac fibroblast cultures treated with 1 M ISO or 10 M NE (a naturally occurring catecholamine) for 48 h were immunolabeled with antibodies specific for CDK1. The percentages of CDK1 positive cardiac fibroblasts were significantly higher in both ISO-and NE-treated cultures compared with their respective control cultures (1.7-to 3.3-fold; Fig. 2, B and C) .
In the second set of experiments, we cultured dispersed cells prepared from E15.5 ventricles. These primary embryonic ventricular cultures were found to contain 64 Ϯ 5% cardiomyocytes (MF20 positive) and 36 Ϯ 5% nonmyocytes (MF20 negative) by antisarcomeric myosin immunostaining using MF20 antibodies (Fig. 3A) . Further immunostaining analysis revealed that the nonmyocyte population contained mainly cardiac fibroblasts as evidenced by positive staining for a well-established fibroblast marker, m (21) (Fig. 3C) . In addition, none of the E15.5 ventricular cells stained positive for the endothelial cell marker von Willebrand factor (14) (Fig. 3B) . It should be noted that ␣-smooth muscle actin is also expressed in embryonic cardiomyocytes and thus cannot be used as a bona fide marker to distinguish embryonic cardiac fibroblasts from cardiomyocytes (9) . E15.5 primary ventricular cultures treated with 1 M ISO for 48 h were immunolabeled with antibodies specific for sarcomeric myosin and CDK1 (Fig. 3 , E and F). There was no significant difference in the percentage of CDK1-positive cardiomyocytes between control and ISOtreated cultures (Fig. 3G) . In contrast, the percentage of CDK1-positive noncardiomyocytes was significantly increased in ISO-treated cultures compared with that of control cultures (ϳ1.6-fold; control: 14.6 Ϯ 2.7 vs. ISO: 23.9 Ϯ 3.2; Fig. 3G ). Collectively, these results confirm that ISO treatment can significantly increase CDK1 protein levels in cardiac fibroblasts of the adult as well as embryonic ventricles under both in vivo and in vitro experimental conditions.
ISO treatment increases endogenous CDK1 mRNA expression and promotes cardiac fibroblast proliferation in E15.5 cultures. To examine the effect of ISO on CDK1 transcription, qPCR was performed on total RNA obtained from the E15.5 cells treated with ISO for either 30 min or 4 h. CDK1 gene induction was normalized to expression levels of mouse RPB1 transcript. qPCR analysis revealed a significant increase in endogenous CDK1 mRNA expression after 30 min of ISO treatment (ϳ77-fold; Fig. 3H ). However, this increase in CDK1 mRNA transcription was not sustained after 4 h (Fig.  3H ) of drug treatment as well as at 12 and 24 h time points (data not shown).
We next examined the effect of ISO on cell cycle control in E15.5 ventricular cell cultures using a [ H]thymidine for an additional 6 h. Subsequently, cells were processed for CDK1 and MF20 dual immunostaining and in situ thymidine autoradiography (Fig. 4, A-C) . There was no significant difference in the percentage of cardiomyocytes positive for thymidine uptake between the control and the ISO-treated cultures (Fig. 4D) . In contrast, the percentage of fibroblasts positive for thymidine uptake was significantly higher in ISO-treated cultures compared with control cultures (1.7-fold; 25.8 Ϯ 5.1% in control vs. 43.1 Ϯ 3.9% in ISO-treated; Fig. 4D ). These results indicate that ISO treatment preferentially increases CDK1 expression and the proliferation of cardiac fibroblasts in primary ventricular cell cultures. To further characterize the effects of ISO on CDK1 expression, we attempted to transfect CDK1-luciferase promoter constructs in adult cardiac fibroblast using conventional gene transfer approaches without any success. In contrast, we found that E15.5 ventricular fibroblasts can be readily transfected with a plasmid vector harboring a lacZ reporter gene (ϳ30% transfection efficiency, data not shown). Since it is relatively easy to transfect embryonic primary ventricular cultures compared with adult cardiac fibroblast cultures using conventional transfection methods, we chose the E15.5 ventricular cultures to further characterize the effects of ISO on CDK1 expression in vitro.
To gain additional mechanistic insights into the regulation of CDK1 gene expression, E15.5 ventricular cultures were transfected with luciferase reporter constructs driven by various lengths of the 5=-flanking region of the human CDK1 gene (100-bp to 6.2-kb CDK1p-luc) in the presence and absence of 1 M ISO (Fig. 5, A-C) . A reporter gene expressing renilla luciferase under the control of the TK promoter was cotransfected with the luciferase reporter to normalize for variations in transfection efficiency between groups. We first assessed the background luciferase activity from an empty pGL2 basic vector and found that the corrected luciferase values from the vector control were negligible (RLU/mg: 0.02 Ϯ 0.003; Fig.  5B ). Compared with the empty vector activity, the basal promoter activities of all CDK1p-luc constructs (in the absence of ISO) were significantly higher, with corrected RLUs ranging from 11 to 22. However, there was no significant difference between the basal promoter activities of all CDK1p-luc deletion constructs used in this study (Fig. 5B) .
Further, ISO treatment was able to significantly increase the activities of all CDKp-luc constructs with the exception of Ϫ245-bp construct compared with the basal promoter activities of the respective constructs in vehicle-treated cultures (Fig.  5B) . When promoter activities were compared as relative fold changes for each construct in the presence or absence of drug treatment, both the largest (6.2 kb) and smallest (100 bp) promoter constructs revealed an approximately twofold induction in response to the drug treatment (Fig. 5C ). In addition, the Ϫ1.1-kb CDK1p-luc construct revealed the maximal response to drug treatment (3.2-fold). Collectively, these results demonstrate the ability of ISO to activate the human CDK1 promoter and suggest that Ϫ100-bp minimal CDK1 promoter region contains the putative positive-responsive element(s) required for the ISO-mediated induction.
The human CDK1 promoter (Ϫ100-bp region) has two NF-Y binding sites but no known ISO-responsive element(s).
Given that the ISO response was mapped to the Ϫ100-bp CDK1 minimal promoter fragment, we compared the proximal Ϫ180 nucleotide sequences of human and mouse CDK1 genes. There is a high degree of sequence homology (82%) between the human and mouse proximal 5=-flanking sequences (Fig. 6) 25, 31). These sequences were further analyzed by the transcription factor search software www.cbrc.jp/research/db/TF-SEARCH to identify known ISO-responsive elements. Although, the search did not reveal any known ISO-responsive element(s) such as cAMP-responsive element, two previously characterized NF-Y binding sites (Ϫ78-to Ϫ74 bp and Ϫ46-to Ϫ42 bp) were identified ( Fig. 6) (31) . Notably, the distal NF-Y binding site (Ϫ78 to Ϫ74 bp) of CDK1 promoter has been suggested to be important for the developmental regulation of a hybrid CDK1p-luc construct in the rat heart (31). The search also showed the well characterized E2F, cell cycledependent element (CDE), and cell cycle gene homology region (CHR) elements as well as two Sp1 sites within the Ϫ180-bp sequence region (Fig. 6) (2, 30, 62) .
The NF-Y transcription factor is a trimeric complex consisting of the NF-YA, NF-YB, and NF-YC subunits. The NF-YA subunit is known to be downregulated in the adult mouse heart and skeletal muscle compared with several other tissues (16); however, there is no information on the expression profiles of NF-Y subunits in the embryonic mouse ventricle. Western blotting was performed with protein lysates from embryonic and adult mouse ventricles to confirm the developmental expression pattern of NF-YA and NF-YB subunits. NF-YA expression was downregulated in the adult ventricles compared with embryonic ventricles while the expression of NF-YB was unchanged (Fig. 7A) . Notably, NF-Y transcription factors were shown to regulate basal and cAMP-stimulated transcriptional activation of the tryptophan hydroxylase (TPH) gene in the pineal gland (11) . Given the ability of ISO to induce cAMP in ventricular cells (58, 59) , we further examined the role of NF-Y transcription factor subunits in the regulation of CDK1 promoter activity under basal and ISO-stimulated conditions in mouse ventricular cell cultures.
Coexpression of wild-type but not NF-YADN activates the Ϫ100-bp CDK1p-luc construct and ISO treatment relieves the promoter repression mediated by NF-YADN. The differential expression pattern of NF-Y subunits is thought to be the primary regulator of CDK1 expression in the adult and embryonic rat heart (31). Consistent with this notion, coexpression of the wild-type NF-YA construct along with the Ϫ100-bp CDK1p-luc significantly increased the promoter activity of the reporter construct by twofold, similar to the fold increase observed with ISO treatment alone (Fig. 7B vs. 5B) . Nevertheless, exposure to ISO along with NF-YA overexpression did not cause a further increase in the CDK1p-luc activity (Fig.  7B) . In contrast, coexpression of an NF-YADN mutant along with the Ϫ100-bp CDK1p-luc construct significantly decreased the promoter activity by threefold compared with controls (Fig. 8) . The NF-YADN coding sequence harbors three point mutations that abolish the DNA binding activity of the NF-YA subunit. When overexpressed, NF-YADN functions as a dominant negative factor by sequestering the NF-YB and NF-YC subunits away from the wild-type NF-YA subunit (33) . Furthermore, ISO treatment relieved the NF-YADN-mediated repression of promoter activity by normalizing the reporter gene levels to those seen with the Ϫ100-bp CDK1p-luc construct alone (Fig. 8) . However, Western blot analysis of protein lysates obtained from cultures treated with or without ISO did not show any significant increase in the expression levels of endogenous NF-YA (data not shown). Taken together, these results support the notion that NF-YA transcription factor plays a critical role in the regulation of basal CDK1 promoter activity and ISO may be involved in the modulation of NF-YA transcriptional activity.
Mutation of the distal NF-Y binding site abolishes basal and ISO-stimulated CDK1 promoter activity. The involvement of NF-Y subunits in the ␤-adrenergic receptor (␤-AR) signal transduction pathway has not been studied in the heart. In light of this, we investigated whether ISO could mediate its effect on the CDK1 promoter directly via NF-Y transcription factors. The role of the distal NF-Y binding site in the ISO-mediated upregulation of Ϫ100-bp CDK1p-luc activity was examined with a mutant 100-bp CDK1 promoter construct that contains two point mutations in the core binding elements of the distal NF-Y binding site (Ϫ100-bp CDK1p-NF-YMTB-luc; Fig. 9 ). These mutations significantly affected the basal promoter activity of the Ϫ100-bp CDK1p-NF-Y MTB-luc construct, which was reduced by 10-fold compared with the wild-type promoter (Fig. 9) . ISO treatment failed to induce the activity of the NF-Y binding site mutant construct to the levels observed with the wild-type Ϫ100-bp construct either in the presence or absence of drug treatment (Fig. 9) . There was no significant difference in the basal and ISO-stimulated promoter activities of the NF-Y binding site mutant construct. Collectively, these results demonstrate that the distal NF-Y binding site is required for the complete induction of the Ϫ100-bp promoter both during basal conditions as well as during ␤-AR stimulation. 
DISCUSSION
We demonstrated that ISO, a nonselective ␤-AR agonist, can increase CDK1 protein levels preferentially in cardiac fibroblasts under both in vivo and in vitro conditions. We further confirmed that treatment of adult cardiac fibroblast cultures with NE, a catecholamine that is naturally occurring in the body, also led to a significant increase in the number of CDK1 expressing cells. Selection of a 10-M dose for NE in this study is based on an earlier report that showed that the relative potency of NE was significantly less than that of ISO in blocking the specific binding of [ 125 I]iodohydroxybenzylpindolol in rat cardiac fibroblast preparations (27) . Furthermore, the NE dose used in our in vitro study is consistent with the peak concentration range of NE (0.3-10 M) in sympathetic nerve synapses (5) .
In this study, osmotic pumps were used to deliver ISO at the rate of 20 mg·kg body wt Ϫ1 ·day Ϫ1 over a 7-day period for in vivo experiments. Although we have not studied the effects of continuous delivery of ISO on the resistance of adrenergic response, it was shown that ISO delivered at the rate of 30 mg·kg body wt Ϫ1 ·day Ϫ1 over a 13-to 14-day period in mice led to ␤-AR desensitization as well as a significant decrease in ␤-AR density in cardiac membranes prepared from ISO-treated mice compared with those of control mice (20, 26) . While the ISO dose and delivery times in our study are not exactly the same as those reported by Iaccarino et al. (20) and Kudej et al. (26) , it is likely that continuous short-term ISO treatment (7 day) would have also dampened ␤-AR function in our study. This notion is consistent with another report, where it was shown that short-term treatment of adult rat ventricular myocyte cultures treated with 1 M ISO for 24 h, compared with controls, was sufficient to significantly increase the levels of ␤-adrenergic receptor kinase 1 (␤ARK1), an enzyme involved in the desensitization of ␤-ARs (19) . Based on this report, it is likely that one-time treatment of 1 M ISO for 48 h would have led to the dampening of adrenergic responses in our primary culture studies. Despite these regulatory effects, it should be noted that significant increases in CDK1 expression were seen in both in vivo and in vitro experiments in this study. Nonetheless, it would be interesting to examine the parameters such as ␤-AR desensitization and ␤-AR density in adult cardiac fibroblast cultures treated with different doses of synthetic and naturally occurring catecholamines in future studies.
Although ISO treatment significantly increased CDK1 expression in cardiac fibroblasts from both adult and embryonic ventricles, the majority of mechanistic studies in this report were mainly focused on E15.5 ventricular cultures primarily due to a poor transfection efficiency of adult cardiac fibroblast cultures with plasmid-based transfection methodologies. Additional in vitro experiments using E15.5 cultures confirmed that ISO increases transcription of the CDK1 gene through a distal NF-Y binding site. The mouse CDK1 5=-flanking sequence is relatively less characterized compared with the human sequence (6, 22, 25, 31) . Given that human promoter deletion constructs have been thoroughly validated in both human cell lines (6, 25) and rat primary ventricular myocyte cultures (31), we chose a heterologous system in this study. Moreover, the proximal 5=-flanking region (Ϫ184 bp) of the mouse CDK1 gene obtained from a genomic clone containing the exon 1 sequence is highly homologous to the well-characterized proximal human CDK1 promoter region (Fig. 6) (2, 22, 25, 31) .
ISO treatment of E15.5 ventricular cells activated the shortest CDK1 construct (Ϫ100-bp CDK1p-luc) by two-to threefold, indicating that the ISO-responsive element(s) in the CDK1 promoter is likely located within this region. One possible mechanism for ISO-mediated effects on promoters is via cAMP-responsive elements (CRE) (18) . A careful examination of our 100-bp promoter region for transcription binding elements by TF search software did not reveal any ISOresponsive CRE elements (Fig. 6 ). Studies on rat TPH (11) and rat hexokinase II (39) promoters showed that ISO and other cAMP-elevating agents such as forskolin were able to increase the transcription of these genes via an NF-Y binding site in their promoter. We identified two such NF-Y binding elements (inverted CCAAT sequence) at Ϫ78 to Ϫ74 bp and Ϫ46 to Ϫ42 bp in our Ϫ100-bp CDK1p-luc construct (Fig. 6) . Further, Liu et al. (31) showed that the NF-Y transcription factor regulates basal CDK1 expression in embryonic rat cardiomyocytes. In light of this, the role of the NF-Y transcription factor in ISO-stimulated CDK1 promoter activation was examined.
The NF-Y transcription factor consists of three subunits, NF-YA, YB, and YC. These subunits form a trimeric complex, and all three are required for the activity of the NF-Y transcription factor (32) . The NF-YA subunit harbors the DNA binding domain and offers specificity to the trimer, which can then bind both CCAAT and inverted CCAAT (ATTGG) sequences on target promoters (32). Farina et al. (13) reported that, in terminally differentiated skeletal muscle cells, the downregulation of the cyclin B1 gene is in part due to a lack of NF-YA expression. In agreement with an earlier report by Gurtner et al. (16) , we found a marked downregulation in NF-YA expression in the adult mouse heart (Fig. 7A) . The lack of sufficient levels of NF-YA expression may be responsible for the developmental downregulation of CDK1 in the adult heart. Therefore, the activity of the Ϫ100-bp CDK1p-luc construct under increased expression of the NF YA subunit was assessed. Results showed that overexpression of the NF-YA subunit along with the Ϫ100-bp CDK1p-luc construct increased promoter activity by twofold similar to the levels that we observed with ISO treatment (Fig. 7B) .
The dominant negative NF-YA subunit (NF-YADN/NF-YA29) has three amino acid mutations in its DNA binding domain and cannot bind to the CCAAT or ATTGG elements in NF-Y target promoters (33) . However, NF-YADN can efficiently trimerize with YB and YC subunits and act as a negative complex by sequestering the YB and YC subunits away from the wild-type NF-YA subunit (33, 51) . Overexpression of this subunit in promoter studies is widely used to determine the NF-Y-dependent regulation of gene promoters (31, 51, 60) . In our study, overexpression of the NF-YADN subunit suppressed the activity of the Ϫ100-bp promoter (Fig.  8) . Interestingly, ISO treatment of cultures cotransfected with the Ϫ100-bp promoter and the NF-YADN construct relieved the NF-YADN-mediated suppression of the Ϫ100-bp promoter (Fig. 8) . Since ISO treatment does not lead to a significant increase in endogenous levels of NF-YA (G. J. Gaspard and K. B. Pasumarthi, unpublished data), it is possible that ISO may trigger posttranslational modifications and increase the binding affinity of wild-type NF-Y to compete with the dominant negative complexes. This notion is further supported by the absence of ISO-stimulated promoter activation upon mutation of the distal NF-Y binding site. The same binding site mutation was also sufficient to prevent basal transcription of the CDK1 promoter in embryonic mouse (this study) as well as rat ventricular cells (31) .
NF-Y-mediated basal and ISO-stimulated promoter activation may be mechanistically similar to that reported for CREB and ATF-1 both of which appear to regulate basal gene transcription by constitutive binding. Phosphorylation of CREB and ATF-1 by protein kinase A (PKA) was shown to enhance the rate of transcription of different target genes (29, 37, 48) . Notably, cAMP responsiveness of the human TPH gene and the fatty acid synthase gene was mapped to the inverted CCAAT box sequences (ATTGG) similar to the sequence motifs present in the CDK1 promoter (7, 43) . Since ISO is known to increase cAMP levels and PKA activation through both ␤ 1 -and ␤ 2 -ARs in myocardial cells (58, 59) , PKA-mediated phosphorylation of NF-Y may account for the effects of ISO on CDK1 transcription. Although the mouse NF-YA primary sequence (P23708; UniProt/Swiss-Prot) lacks a consensus PKA site (-Arg-Arg-XSer-; Ref. 48) , involvement of an atypical serine phosphorylation site at amino acid 319 (-Arg-X-X-Ser-) as a target for PKA or additional protein kinases such as Ca 2ϩ /calmodulin-dependent kinases (CaMK) cannot be ruled out. Indeed, the -Arg-X-X-Ser-sequence was suggested to be the minimum specificity determinant for the CaMKII (10) . Similarly, ISO may alter the ability of constitutively active repressor binding proteins in the Ϫ100-bp promoter region and indirectly enhance NF-Y-mediated transcription. Indeed, two repressor elements, CDE and CHR, were mapped very close to NF-Y binding sites in the Ϫ100-bp promoter region (2) and their role in basal and ISO-stimulated cardiac fibroblast proliferation warrants further investigation.
Conclusion. Findings from this study identified two new targets (CDK1 and NF-Y) involved in cardiac fibroblast proliferation. This raises an exciting possibility that targeting these two players in the adult heart during disease states may lead to decreased cardiac fibrosis. A potential pitfall associated with this approach is the complete abrogation of cardiac fibroblast proliferation subsequently leading to defects in the infarct wound healing. However, reactive fibrosis is also seen in patients with cardiac hypertrophy induced by chronic pressure overload or hypertension. Reactive fibrosis is due to uncontrolled proliferation of cardiac fibroblasts, which is not related to infarct wound healing. Therefore, targeting CDK1 or NF-Y in this setting could be useful in reducing the modifier effect of fibrosis on the disease outcome and may offer cardioprotective benefits. Fig. 9 . Role of distal NF-Y binding site in basal and ISO-induced CDK1 promoter activation. Two point mutations in the distal NF-Y binding site of the Ϫ100-bp CDK1p-Luc construct (NF-Ybsmt-100-bp CDK1p.Luc) repressed the basal promoter activity by 10-fold compared with the wild-type promoter construct. ISO treatment significantly increased the activity of the Ϫ100-bp wild-type promoter construct but not that of the Ϫ100-bp promoter harboring point mutations in the distal NF-Y binding site. Promoter activities are expressed as mean luciferase RLU/renilla RLU/mg of protein (corrected RLU) Ϯ SE. *P Ͻ 0.005, compared with all other groups; *P Ͻ 0.05, compared with other groups except Ϫ100-bp NFYmtbs CDK1p-Luc ϩ ISO; #P Ͻ 0.005, compared with Ϫ100-bp CDK1p-Luc ϩ ISO but not other groups by ANOVA with Tukey's multiple comparison test; n ϭ 3 independent experiments with 2 replicates per group in each experiment.
